{"title":"Temporary Mechanical Support in Cardiogenic Shock Secondary to Heart Failure: An Evolving Paradigm.","authors":"Nandini Nair, Dongping Du, Balakrishnan Mahesh","doi":"10.3390/jpm15050184","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiogenic shock can be defined as a state of circulatory collapse resulting in hypoperfusion and end-organ dysfunction. It carries a large burden of mortality, but management strategies are driven by expert consensus rather than adequately powered randomized clinical trials. The goal of this review is to highlight the differences in presentation and outcomes in cardiogenic shock depending on the etiology, such as acute myocardial infarction (AMI) versus acute-on-chronic heart failure (HF), gender-based differences in treatment strategies and outcomes and the need for more precise risk stratification and modeling to improve the efficiency of treatment delivery in a personalized fashion. PubMed and Google Scholar were used to search the literature for this qualitative review. The differences in gender and etiology of cardiogenic shock are not consistent in all studies in the exiting literature. There is a need for identification of novel risk factors that define the different phenotypes that present with similar hemodynamic and biomarker profiles. There is an urgent need to devise a methodology to understand and differentiate the different cardiogenic shock phenotypes and their trajectories. Better risk prediction models should be generated to help deliver well-tailored treatment, paving the way to the efficient delivery of personalized medicine.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 5","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12113383/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm15050184","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Cardiogenic shock can be defined as a state of circulatory collapse resulting in hypoperfusion and end-organ dysfunction. It carries a large burden of mortality, but management strategies are driven by expert consensus rather than adequately powered randomized clinical trials. The goal of this review is to highlight the differences in presentation and outcomes in cardiogenic shock depending on the etiology, such as acute myocardial infarction (AMI) versus acute-on-chronic heart failure (HF), gender-based differences in treatment strategies and outcomes and the need for more precise risk stratification and modeling to improve the efficiency of treatment delivery in a personalized fashion. PubMed and Google Scholar were used to search the literature for this qualitative review. The differences in gender and etiology of cardiogenic shock are not consistent in all studies in the exiting literature. There is a need for identification of novel risk factors that define the different phenotypes that present with similar hemodynamic and biomarker profiles. There is an urgent need to devise a methodology to understand and differentiate the different cardiogenic shock phenotypes and their trajectories. Better risk prediction models should be generated to help deliver well-tailored treatment, paving the way to the efficient delivery of personalized medicine.
期刊介绍:
Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.